Ischemic stroke in patients with solid gynecologic tract tumors and coagulopathy

Eur Neurol. 2013;70(5-6):304-7. doi: 10.1159/000353799. Epub 2013 Sep 24.

Abstract

Aim: Patients with gynecological neoplasms often suffer ischemic stroke. This study aimed to clarify the underlying mechanisms of ischemic stroke in patients with gynecological tract tumors.

Methods: We retrospectively reviewed 6 patients with gynecologic tumors and hypercoagulability who were being treated for acute ischemic stroke between 2006 and 2012. Diffusion-weighted magnetic resonance imaging (DW-MRI), cardiovascular risk factors including plasma D-dimer levels, and histologic examination of the patients' solid tumors were performed. All 6 patients underwent transesophageal echocardiography (TEE) for nonbacterial thrombotic endocarditis (NBTE) and paradoxical embolism.

Results: All 6 patients showed elevated plasma D-dimer levels. In 1 patient, paradoxical embolism was diagnosed. In the remaining 5 patients, DW-MRI scans showed numerous lesions in multiple vascular territories, and in 4 of these 5 patients, TEE demonstrated vegetations on the mitral valve, leading to the diagnosis of NBTE. Interestingly, 2 of these 4 patients had benign uterine tumors, whereas the other 2 had ovarian cancer.

Conclusions: NBTE was the main etiology for ischemic stroke in patients with gynecologic tract tumors and coagulopathy. Both malignant and benign tumors of the gynecologic tract can cause NBTE.

MeSH terms

  • Adult
  • Disseminated Intravascular Coagulation / complications*
  • Echocardiography, Transesophageal / methods
  • Endocarditis / complications*
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Genital Neoplasms, Female / complications*
  • Genital Neoplasms, Female / pathology
  • Humans
  • Magnetic Resonance Imaging / methods
  • Male
  • Middle Aged
  • Myocardial Ischemia / complications*
  • Myocardial Ischemia / pathology
  • Retrospective Studies
  • Stroke / diagnosis
  • Stroke / etiology*
  • Stroke / pathology

Substances

  • Fibrin Fibrinogen Degradation Products
  • fibrin fragment D